AnaptysBio (ANAB)
(Real Time Quote from BATS)
$30.99 USD
+0.67 (2.21%)
Updated Jul 12, 2024 11:30 AM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ANAB 30.99 +0.67(2.21%)
Will ANAB be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ANAB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ANAB
Repligen (RGEN) Soars 4.4%: Is Further Upside Left in the Stock?
AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates
ANAB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Tops Revenue Estimates
Guardant (GH) Gears Up for Q1 Earnings: Here's What to Expect
Iovance (IOVA) Gears Up for Q1 Earnings: Here's What to Expect
Other News for ANAB
Analysts Offer Insights on Healthcare Companies: Urogen Pharma (URGN), AnaptysBio (ANAB) and Sarepta Therapeutics (SRPT)
Truist Financial Sticks to Its Hold Rating for AnaptysBio (ANAB)
AnaptysBio price target raised by $1 at JPMorgan, here's why
Analysts Have Conflicting Sentiments on These Healthcare Companies: ARS Pharmaceuticals (SPRY), AnaptysBio (ANAB) and Allakos (ALLK)
Wedbush Reaffirms Their Buy Rating on AnaptysBio (ANAB)